沙巴体育

About Us
Overview
Our History
Leadership Team
Partner
Portfolio Advisory Board
Media Center
Our Science
Science & Innovation
Dorzagliatin
mGluR5
Presentations
Peer Reviewed Publications
Products&Pipeline
Pipeline
HuaTangNing(华堂宁®)
Media
Company News
Media Releases
Video
Investor Relations
Investor Center
Corporate Governance
Financial Report
Announcements and Circulars
Listing Documents
Investor Presentation
IR Contact
Investor Calendar
Stock Information (2552.HK)
Corporate Communications
Careers
Company Culture
Join Us
Contact Us
中
中
中

  • Media

  • Investor Relations

  • Careers

  • Contact Us

    • Products&Pipeline

    > Products&Pipeline
    > Pipeline
    Pipeline
    HuaTangNing(华堂宁®)

    Pipeline

    Product and Pipeline
    Indication
    Discovery
    (Pre-clinical-Phase II)
    Development
    (Phase III)
    Commercialization
    Dorzagliatin
    T2D - Drug Naïve
    T2D - Metformin Tolerated
    RWE study for Diabetes Remission
    MODY-2
    Diabetes prevention IGT2NGT
    Frailty
    Early AD
    CFRD
    Dorzagliatin and Metformin FDC
    T2D
    2nd Generation GKA
    Metabolic Disease
    Dorzagliatin add on to GLP1RAs
    T2D and Obesity
    Dorzagliatin + small molecule GLP-1
    T2D and Obesity
    Dorzagliatin + Empagliflozin
    DKD
    Dorzagliatin + Sitagliptin
    T2D
    Dorzagliatin add on to Insulin
    Insulin sparing in T2D
    mGLUR5 NAM
    PD-LID
    Drug Addiction
    GK NAM
    Metabolic Disease
    Dorzagliatin
    Discovery
    (Pre-clinical-Phase II)
    Development
    (Phase III)
    Commercialization
    T2D - Drug Naïve
    T2D - Metformin Tolerated
    RWE study for Diabetes Remission
    MODY-2
    Diabetes prevention IGT2NGT
    Frailty
    Early AD
    CFRD
    Dorzagliatin and Metformin FDC
    Discovery
    (Pre-clinical-Phase II)
    Development
    (Phase III)
    Commercialization
    T2D
    2nd Generation GKA
    Discovery
    (Pre-clinical-Phase II)
    Development
    (Phase III)
    Commercialization
    Metabolic Disease
    Dorzagliatin add on to GLP1RAs
    Discovery
    (Pre-clinical-Phase II)
    Development
    (Phase III)
    Commercialization
    T2D and Obesity
    Dorzagliatin + small molecule GLP-1
    Discovery
    (Pre-clinical-Phase II)
    Development
    (Phase III)
    Commercialization
    T2D and Obesity
    Dorzagliatin + Empagliflozin
    Discovery
    (Pre-clinical-Phase II)
    Development
    (Phase III)
    Commercialization
    DKD
    Dorzagliatin + Sitagliptin
    Discovery
    (Pre-clinical-Phase II)
    Development
    (Phase III)
    Commercialization
    T2D
    Dorzagliatin add on to Insulin
    Discovery
    (Pre-clinical-Phase II)
    Development
    (Phase III)
    Commercialization
    Insulin sparing in T2D
    mGLUR5 NAM
    Discovery
    (Pre-clinical-Phase II)
    Development
    (Phase III)
    Commercialization
    PD-LID
    Drug Addiction
    GK NAM
    Discovery
    (Pre-clinical-Phase II)
    Development
    (Phase III)
    Commercialization
    Metabolic Disease
    About Us
    Overview
    Our History
    Leadership Team
    Portfolio Advisory Board
    Partner
    Media center
    Research & Development
    Inovation
    Dorzagliatin
    mGluR5
    Presentations
    Peer Reviewed Publications
    Media
    Company News
    Media Releases
    Video
    Investor Relations
    Corporate Governance
    Financial Report
    Announcements & Circulars
    Listing Documents
    Investor Presentation
    IR Contact
    Investor Calendar
    Stock information
    Careers
    Culture
    Join Us
    Products&Pipeline
    Pipeline
    HuaTangNing(华堂宁®)
    Focus Us
    Copyright © 2026 Hua Medicine (Shanghai) Ltd. 沪网药械信备字【2026】000123号
    沪ICP备14036654号-1 beiantubiao.png 沪公网安备 31011502013809号 Privacy Statement Terms of Use
    Search
    How we use cookies
    Hua Medicine uses cookies to enable and improve the use of the website. By continuing to use the site, you consent to the use of these cookies. To learn more about cookies, please read our privacy statement.
    Accept
    x
    ag8亚游